By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan ...

Although Pfizer has seen better revenue growth in recent years, AbbVie is more profitable.

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

Pfizer just got an approval for a drug to treat ulcerative colitis. AbbVie is still trying to consolidate its control over that market. Pfizer doesn't need a total victory to make things harder ...

The stock's fall snapped a three-day winning streak.

Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. It is unlikely that the Inflation Reduction Act will have ...

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

AbbVie has done better than BMW and Pfizer because most of its growth has been organic. While it has spent billions in acquisitions, it has not been as aggressive.

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune ...

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.